<DOC>
	<DOCNO>NCT00695344</DOCNO>
	<brief_summary>The purpose study evaluate significantly less incidence major clinical event due graft vascular illness recipient cardiac transplant treatment immunosuppressive combination , include Everolimus , compare continue previously use immunosuppressive treatment .</brief_summary>
	<brief_title>Study Evaluate Effect Everolimus Progression Graft Vascular Illness Patients With Heart Transplant</brief_title>
	<detailed_description>This prospective , randomize , multicentre , open control study , evaluate efficacy safety everolimus combine cyclosporin microemulsion steroid accord medical judgement , opposite usual therapy patient already receive ( typically : ciclosporin + azathioprine mycophenolate mofetil + steroid accord judgement doctor ) patient receive cardiac orthotopic transplant since least 12 month . The patient randomize 2:1 proportion ( everolimus : control ) , order make possible majority patient receive potentially active treatment lethal illness efficient know treatment date . The study duration 2 year follow-up patient . At end period , patient offer possibility maintain immunosuppressive treatment assign , periodic revision make 3-6 month . The two treatment group : Group I - Everolimus twice day v.o . + cyclosporin microemulsion reduce dos +/- steroid . Group II - Cyclosporin microemulsion + azathioprine mycophenolate mofetil +/- steroid ( administration schedule medication patient receive earlier ) .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Patients suffer heart transplantation least 12 month inclusion . Patients significant graft vascular cardiac illness . Patients receive one solid organ . Hypersensibility everolimus . Patients expect survive less 6 month . Analytic abnormality significant ( platelet &lt; 70.000 plat./mm3 , WBC &lt; 4.000./mm3 , creatinine &gt; 2,5 mg/dl ) Neoplasm and/or severe systemic illness . Mental significant illness . Patients receive sirolimus everolimus moment transplant . Pregnant lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Effect everolimus graft vascular cardiac illness</keyword>
</DOC>